Coeptis Therapeutics Hldgs Inc (COEP) Stock Price, Quote & News

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology

Sector: Healthcare

Phone: 724 934 6467

Website: coeptistx.com

Address:

105 Bradford Road, Suite 420, Wexford, United States

futuregssummeranalyst Oct. 4 at 2:35 AM

$COEP make me rich

0 · Reply

NEWBIGTECH Oct. 3 at 3:37 PM

$ESPR Same for $COEP $SLS $SOUN. ALL 4 STOCKS SET TO MOVE UP TO. THE EAST SIDE.

1 · Reply

bionicman1969 Oct. 3 at 3:22 PM

$COEP pro forma valuation is silly. Keep selling. Congrats to longs for now.

0 · Reply

Iiii1ii Oct. 3 at 2:49 PM

$COEP Anything under $25 is a gift

0 · Reply

Iiii1ii Oct. 3 at 2:32 PM

$COEP Maintaining a large position in COEP before the news announcement, a bullish move of $30+, a merger value of $100+

0 · Reply

AllAmerican82ndAirborne Oct. 3 at 11:22 AM

$COEP keep dreamin mate 😂

0 · Reply

RyGuy5000 Oct. 2 at 9:39 PM

$COEP there is a legal obligation to disclose the closure when it happens.

1 · Reply

o____o Oct. 2 at 7:27 PM

$COEP Feels like Z Squared news would not hit as hard unless it was timed into a dogecoin rally, which at this point seems to be at the beginning stages with the doge ETF's popping up, price rising, October, etc.. Almost better that they hold off until it runs. It's actually nuts how some well timed news here could send this to the stratosphere. I'm loaded up and ready.

0 · Reply

1Spartantrade1 Oct. 2 at 7:04 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $BNGO $BQ $ATCH $COEP

1 · Reply

makedatbread88 Oct. 2 at 2:36 PM

$COEP fair value $41+ And you can buy it here still cheap under $20 🤷‍♂️ This 2M float massive pending crypto merger will be a MONSTER… congrats to those who listen 😊🚀 ***Follow me for more winning calls!***

1 · Reply

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Jul 22, 2025, 8:36 AM EDT - 2 months ago

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jun 26, 2025, 8:34 AM EDT - 3 months ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

May 28, 2025, 8:28 AM EDT - 4 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Apr 25, 2025, 8:33 AM EDT - 5 months ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 17, 2025, 8:38 AM EDT - 6 months ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Mar 11, 2025, 8:34 AM EDT - 7 months ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 7, 2025, 8:37 AM EST - 7 months ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 7 months ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

Feb 20, 2025, 9:00 AM EST - 8 months ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 7:27 AM EST - 8 months ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 13, 2025, 8:39 AM EST - 8 months ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 6, 2025, 8:08 AM EST - 8 months ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Jan 30, 2025, 8:27 AM EST - 8 months ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 23, 2025, 8:09 AM EST - 9 months ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 22, 2025, 8:00 AM EST - 9 months ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 7, 2025, 8:00 AM EST - 9 months ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Dec 27, 2024, 8:15 AM EST - 10 months ago

Coeptis Therapeutics Announces Reverse Stock Split

Dec 26, 2024, 8:15 AM EST - 10 months ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 10 months ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 3, 2024, 8:15 AM EST - 10 months ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Nov 7, 2024, 8:07 AM EST - 11 months ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Oct 24, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 15, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Sep 19, 2024, 7:07 AM EDT - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

May 30, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 8, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Feb 26, 2024, 9:00 AM EST - 1 year ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 7, 2024, 7:30 AM EST - 1 year ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Jan 4, 2024, 7:30 AM EST - 1 year ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Dec 4, 2023, 7:30 AM EST - 1 year ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 24, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 9, 2023, 9:15 AM EDT - 2 years ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

$Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection$

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Aug 30, 2023, 1:00 PM EDT - 2 years ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 17, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Jun 16, 2023, 4:00 PM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Jun 14, 2023, 9:28 AM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Jun 9, 2023, 7:00 AM EDT - 2 years ago

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

futuregssummeranalyst Oct. 4 at 2:35 AM

$COEP make me rich

0 · Reply

NEWBIGTECH Oct. 3 at 3:37 PM

$ESPR Same for $COEP $SLS $SOUN. ALL 4 STOCKS SET TO MOVE UP TO. THE EAST SIDE.

1 · Reply

bionicman1969 Oct. 3 at 3:22 PM

$COEP pro forma valuation is silly. Keep selling. Congrats to longs for now.

0 · Reply

Iiii1ii Oct. 3 at 2:49 PM

$COEP Anything under $25 is a gift

0 · Reply

Iiii1ii Oct. 3 at 2:32 PM

$COEP Maintaining a large position in COEP before the news announcement, a bullish move of $30+, a merger value of $100+

0 · Reply

AllAmerican82ndAirborne Oct. 3 at 11:22 AM

$COEP keep dreamin mate 😂

0 · Reply

RyGuy5000 Oct. 2 at 9:39 PM

$COEP there is a legal obligation to disclose the closure when it happens.

1 · Reply

o____o Oct. 2 at 7:27 PM

0 · Reply

1Spartantrade1 Oct. 2 at 7:04 PM

1 · Reply

makedatbread88 Oct. 2 at 2:36 PM

1 · Reply

Iiii1ii Oct. 2 at 1:47 PM

$COEP

0 · Reply

Iiii1ii Oct. 2 at 12:07 AM

$COEP Anything below $20 is a gift. Unlimited purchase.

0 · Reply

futuregssummeranalyst Oct. 1 at 9:15 PM

$COEP im getting hype

0 · Reply

AllAmerican82ndAirborne Oct. 1 at 8:06 PM

$COEP $QNTM Which one is first to $100?

0 · Reply

Fluteman_Greg Oct. 1 at 7:28 PM

$COEP In the S-4 filing regarding the merger, Z Squared said that mining Doge was profitable when DOGE is trading between .11 - .21, depending on the mining platform used. DOGE is currently at .2475

0 · Reply

Jeko44 Oct. 1 at 11:32 AM

$COEP

0 · Reply

Iiii1ii Oct. 1 at 4:23 AM

$COEP $100 imminent!!

0 · Reply

RyGuy5000 Sep. 30 at 6:26 PM

$COEP hoping for pre market news tomorrow

0 · Reply

Fluteman_Greg Sep. 30 at 5:07 PM

$COEP Merger must be getting very close.

0 · Reply

o____o Sep. 30 at 4:41 PM

$COEP

0 · Reply

NEWBIGTECH Sep. 30 at 3:23 PM

$COEP Coeptis Therapeutics Holdings, Inc, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

0 · Reply

The1Albatross Sep. 30 at 12:38 PM

$COEP https://vanderbiltreport.com/coeptis-therapeutics-anchoring-z-squareds-800m-valuation/

4 · Reply

Market Cap	81.95M
Revenue (ttm)	0.00
Net Income (ttm)	-10.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.02

Volume	48,100
Avg Vol	54,288
Day's Range	N/A - N/A
Shares Out	4.82M
Stochastic %K	42%
Beta	-0.49
Analysts	Strong Buy
Price Target	$3.00